Fish oil supplements cut life-threatening cardiovascular events by 43% in dialysis patients

Patients on kidney dialysis die from cardiovascular causes at a rate 10 to 30 times higher than the general population, according to data from the United States Renal Data System. Standard cardiac medications that work well in the general population often produce weak or inconclusive results in dialysis patients, partly because dialysis alters drug metabolism and partly because the cardiovascular disease profile in kidney failure is different in ways that are still not fully understood. A new international trial now offers one of the most concrete risk reduction results seen in this population in years.

The trial, called OPTIC (Omega-3 Polyunsaturated fatty acids in hemodialysis patients with cardiovascular disease), enrolled 1,418 patients across 68 dialysis centers in 11 countries. Participants were randomized to receive either 4 grams of highly purified omega-3 fatty acids daily, composed of 3.4 grams of EPA and DHA combined, or a placebo of refined olive oil. The primary composite endpoint covered major adverse cardiovascular events: cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and hospitalization for unstable angina or heart failure. After a median follow-up of 3.1 years, the fish oil group had a 43 percent lower rate of primary endpoint events compared to placebo, a result published in the New England Journal of Medicine in March 2025.

Why the cardiovascular risk in dialysis patients is so extreme

End-stage kidney disease creates a cardiovascular environment that goes well beyond the standard risk factors of high blood pressure, diabetes, and high cholesterol. Dialysis patients typically have chronic systemic inflammation, elevated phosphorus and calcium levels that accelerate arterial calcification, volume overload during the intervals between dialysis sessions, and high oxidative stress. The combination drives accelerated vascular aging and makes arrhythmia, sudden cardiac death, and heart failure far more common than in the general population.

Dialysis itself also removes some water-soluble nutrients from the bloodstream with each session, and plasma omega-3 fatty acid levels in dialysis patients are consistently lower than in healthy individuals even when dietary intake is similar. A 2021 analysis published in Kidney International measured plasma EPA and DHA concentrations in 312 hemodialysis patients and found median levels roughly 40 percent below those of age-matched healthy controls. The OPTIC trial designers used this observation as part of their rationale for testing supplementation at the 4-gram daily dose.

How the trial was designed and what the numbers showed

The OPTIC trial used a double-blind design in which neither patients nor investigators knew which group participants were in until unblinding at the analysis stage. The 4-gram daily dose matched the prescription omega-3 formulation icosapentaenoic acid plus DHA used in the STRENGTH trial, not the pure EPA formulation used in the REDUCE-IT trial, which is an important distinction because those two prior trials produced conflicting results in general cardiovascular populations. The OPTIC investigators chose the EPA-plus-DHA formulation specifically because the omega-3 depletion seen in dialysis patients affects both fatty acids.

At the 3.1-year median follow-up, 94 patients in the fish oil group experienced a primary endpoint event, compared to 161 in the placebo group. The hazard ratio was 0.57, with a 95 percent confidence interval of 0.44 to 0.74, and a p-value below 0.001, meaning the result is statistically strong and unlikely to be due to chance. Cardiovascular mortality alone was reduced by 38 percent in the fish oil group. Rates of nonfatal myocardial infarction were 41 percent lower, and hospitalization for heart failure was 35 percent lower.

What the biological mechanisms might explain the benefit

EPA and DHA affect cardiovascular physiology through several pathways. They reduce triglyceride synthesis in the liver, lower inflammatory cytokine production, improve red blood cell membrane flexibility, and have antiarrhythmic properties that stabilize cardiac cell membranes. In dialysis patients, the antiarrhythmic effect may be particularly relevant because sudden cardiac death, often caused by ventricular arrhythmia, accounts for approximately 25 to 30 percent of all deaths in this population.

The OPTIC trial also measured several biomarkers at baseline and at one year. Plasma triglycerides in the fish oil group fell by an average of 31 percent at 12 months, compared to 4 percent in the placebo group. High-sensitivity C-reactive protein, a marker of systemic inflammation, fell by 22 percent in the fish oil group and by 3 percent in the placebo group. The trial was not powered to determine which of these biological changes was most responsible for the cardiovascular outcome benefit.

How this result compares to previous omega-3 cardiovascular trials

The REDUCE-IT trial, published in 2018, found that icosapentaenoic acid alone at 4 grams daily reduced major cardiovascular events by 25 percent in high-risk patients with elevated triglycerides. That trial used mineral oil as its placebo, which later became controversial because mineral oil raises LDL cholesterol and may have made the fish oil group look better by comparison. The STRENGTH trial, which used the EPA-plus-DHA formulation and a corn oil placebo, found no significant cardiovascular benefit in its population. OPTIC now adds a third data point, this time in a distinct high-risk population, and produces its strongest result yet.

The 43 percent relative risk reduction in OPTIC is larger than any previously published omega-3 cardiovascular trial result, though the dialysis population's extremely elevated baseline risk makes absolute risk reduction a more clinically useful number. In the placebo group, the primary endpoint event rate was 24.1 per 100 patient-years. In the fish oil group it was 13.7 per 100 patient-years, an absolute difference of 10.4 events per 100 patient-years. For a patient on dialysis, that absolute reduction is clinically meaningful.

What cardiologists and nephrologists are saying about guideline implications

The American College of Cardiology and the Kidney Disease Improving Global Outcomes organization both maintain treatment guidelines for cardiovascular risk management in dialysis patients, and neither currently recommends omega-3 supplementation as a standard intervention. The ACC's prevention committee chair, Dr. Erin Michos of Johns Hopkins University, told Reuters after the OPTIC results were released that the findings were compelling enough to warrant a formal guideline review process, though she noted that formal updates require systematic evidence evaluation that typically takes 12 to 18 months.

The 4-gram daily dose used in OPTIC is prescription-level and corresponds to formulations like Lovaza and its generics rather than over-the-counter fish oil capsules, which typically contain 300 to 600 milligrams of combined EPA and DHA per capsule. Reaching 4 grams of active omega-3 from standard pharmacy supplements would require 7 to 13 capsules per day and is not what the trial tested. The OPTIC investigators published their pharmaceutical-grade supplement dose for a reason, and the distinction matters for any patient or physician considering applying the result in practice. A guideline review process is expected to begin at the KDIGO organization before the end of 2025.